Drug profile · INN
tepotinib
TEPMETKO
tepotinib (TEPMETKO) is a hepatocyte growth factor receptor inhibitor. Associated with Merck KGaA, Darmstadt, Germany.
EMA: approved TGA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01EX21
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — tepotinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
tepotinib (TEPMETKO) is a hepatocyte growth factor receptor inhibitor. Associated with Merck KGaA, Darmstadt, Germany.
Key facts
INN tepotinib
Brand TEPMETKO
Mechanism Hepatocyte growth factor receptor inhibitor
Target Hepatocyte growth factor receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EX21
Originator Merck KGaA, Darmstadt, Germany
Mechanism of action
Hepatocyte growth factor receptor inhibitor
Primary target: Hepatocyte growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tepotinib?
tepotinib (TEPMETKO) is a hepatocyte growth factor receptor inhibitor. Associated with Merck KGaA, Darmstadt, Germany.
What is the brand name for tepotinib?
TEPMETKO is a marketed brand name for tepotinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.